Solara Active Pharma Sciences Limited SOLARA NSEPHARMA
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immune-suppressant, loop diuretic, NSAIDs, anti-hyperkalaemia, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical development, impurity synthesis, and regulatory support. In addition, the company exports its products. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Profit CAGR of 22.2% over 5 years.
- Generates positive free cash flow.
CONS
- Revenue declined at -0.2% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SOLARA Solara Active Pharma Sciences Limited NSEPHARMA | 532.70 | - | ₹2,566.22 Cr | - | 6.07% | -0.63% | -0.25% | 22.20% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 273.01 Cr | 319.15 Cr | 313.54 Cr | 349.00 Cr | 387.29 Cr |
| Cost of Revenue | - | - | 118.09 Cr | 146.47 Cr | 154.00 Cr | 186.60 Cr | 197.44 Cr |
| Gross Profit | - | - | 154.92 Cr | 172.68 Cr | 159.54 Cr | 162.40 Cr | 189.85 Cr |
| Operating Expenses | - | - | 133.85 Cr | 139.24 Cr | 149.30 Cr | 150.63 Cr | 158.23 Cr |
| Operating Income | - | - | 21.07 Cr | 33.44 Cr | 10.24 Cr | 11.77 Cr | 31.62 Cr |
| EBITDA | - | - | 51.32 Cr | 58.00 Cr | 35.22 Cr | 30.59 Cr | 63.21 Cr |
| Interest Expense | - | - | 29.12 Cr | 23.90 Cr | 20.83 Cr | 22.45 Cr | 27.57 Cr |
| Pretax Income | - | - | -2.10 Cr | 10.52 Cr | -10.10 Cr | -17.43 Cr | 9.60 Cr |
| Tax Provision | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | - | - | -2.10 Cr | 10.52 Cr | -10.10 Cr | -17.43 Cr | 9.60 Cr |
| Diluted EPS | - | - | -0.93 | 2.46 | -2.36 | -3.98 | 2.20 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 1,379.19 Cr | 1,238.39 Cr | 1,283.76 Cr | 1,368.98 Cr |
| Cost of Revenue | - | 813.22 Cr | 838.51 Cr | 626.41 Cr | 684.51 Cr |
| Gross Profit | - | 565.97 Cr | 399.88 Cr | 657.35 Cr | 684.47 Cr |
| Operating Expenses | - | 532.81 Cr | 597.96 Cr | 550.32 Cr | 597.40 Cr |
| Operating Income | - | 33.16 Cr | -198.08 Cr | 107.03 Cr | 87.07 Cr |
| EBITDA | - | 149.75 Cr | -285.27 Cr | 214.60 Cr | 187.02 Cr |
| Interest Expense | - | 83.38 Cr | 99.82 Cr | 114.81 Cr | 94.75 Cr |
| Pretax Income | - | -44.82 Cr | -488.42 Cr | 54.00 L | -7.41 Cr |
| Tax Provision | - | -22.57 Cr | 78.54 Cr | 0 | 0 |
| Net Income | - | -22.18 Cr | -567.39 Cr | 54.00 L | -7.41 Cr |
| Diluted EPS | - | -5.68 | -148.51 | 0.14 | -1.68 |
Compounded Sales Growth
| 5 Years: | -0.25% |
| 1 Year: | 43.60% |
Compounded Profit Growth
| 5 Years: | 22.20% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +10.69% |
| 6 Months: | +1.68% |
| 3 Months: | +12.79% |
| 1 Month: | +8.55% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 2,899.28 Cr | 2,350.96 Cr | 2,231.84 Cr | 2,332.59 Cr |
| Current Assets | - | 1,187.54 Cr | 800.75 Cr | 728.73 Cr | 858.10 Cr |
| Cash & Equivalents | - | 8.73 Cr | 8.44 Cr | 3.95 Cr | 4.48 Cr |
| Inventory | - | 558.09 Cr | 359.70 Cr | 317.90 Cr | 317.87 Cr |
| Receivables | - | 536.99 Cr | 348.52 Cr | 326.57 Cr | 438.72 Cr |
| Total Liabilities | - | 1,396.83 Cr | 1,414.38 Cr | 1,134.93 Cr | 1,077.04 Cr |
| Current Liabilities | - | 1,101.13 Cr | 1,242.85 Cr | 944.11 Cr | 893.91 Cr |
| Long Term Debt | - | 235.10 Cr | 105.83 Cr | 113.86 Cr | 110.45 Cr |
| Total Debt | - | 1,012.85 Cr | 1,011.50 Cr | 796.08 Cr | 686.56 Cr |
| Total Equity | - | 1,500.21 Cr | 933.91 Cr | 1,094.24 Cr | 1,252.88 Cr |
| Shares Outstanding | - | 3.91 Cr | 3.91 Cr | 4.81 Cr | 4.82 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 156.25 Cr | 108.87 Cr | 212.82 Cr | 152.91 Cr |
| Investing Cash Flow | - | -81.14 Cr | -3.51 Cr | -36.83 Cr | -98.83 Cr |
| Financing Cash Flow | - | -112.76 Cr | -105.65 Cr | -180.48 Cr | -53.55 Cr |
| Capital Expenditure | - | -111.31 Cr | -41.06 Cr | -39.94 Cr | -52.82 Cr |
| Free Cash Flow | - | 44.94 Cr | 67.81 Cr | 172.88 Cr | 100.09 Cr |
| Net Change in Cash | - | -37.65 Cr | -29.00 L | -4.49 Cr | 53.00 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 41.0% | 32.3% | 51.2% | 50.0% |
| Operating Margin % | - | 2.4% | -16.0% | 8.3% | 6.4% |
| Net Margin % | - | -1.6% | -45.8% | 0.0% | -0.5% |
| ROE % | - | -1.5% | -60.8% | 0.0% | -0.6% |
| ROCE % | - | 1.8% | -17.9% | 8.3% | 6.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SOLARA